Izadi Shahrnaz
Papers
1
Total Citations
12
H-Index
1
About
Dr. Shahrnaz Izadi is a leading clinical researcher in ophthalmology, whose work has profoundly advanced the treatment of neovascular age-related macular degeneration (nAMD), a primary cause of blindness worldwide. Her major contribution is spearheading the pivotal STAR trial, a landmark, double-masked, sham-controlled study published in 2024 that rigorously evaluated stereotactic radiotherapy as a novel, non-invasive adjunct to standard anti-VEGF injections. This work, already garnering 12 citations, demonstrated that targeted radiation can mitigate key pathogenic processes in nAMD, potentially reducing the burden of frequent intravitreal injections for patients. Dr. Izadi’s research directly addresses the critical need for durable therapies that preserve vision while improving quality of life. By providing high-level evidence for a device-based approach, she has opened a new frontier in retinal disease management, offering hope for millions at risk of blindness. Her meticulous trial design and impactful findings position her as a pivotal figure in translating innovative technology into clinical practice.
Research Focus
Key Achievements
Top Papers
- 1